Form 4: Silexion Director Reports Disputed Share Issuance, Splits

Ilan Levin and Moringa Sponsor report changes in beneficial ownership of Silexion Therapeutics Corp, including a disputed share issuance and warrant adjustments following reverse stock splits.

Summary

• Ilan Levin and Moringa Sponsor, LP. reported changes in beneficial ownership of Silexion Therapeutics Corp (SLXN).
• On August 7, 2025, Moringa Sponsor, LP. conducted a pro rata distribution of 5,550 ordinary shares and 935 warrants to its limited partners for no consideration.
• On September 15, 2025, 450,000 ordinary shares were issued to Moringa Sponsor, LP. upon conversion of $1,800,000 of an outstanding convertible promissory note, with a conversion price of $4.00 per share.
• The reporting persons expressly dispute the validity of the 450,000 share issuance and do not concede beneficial ownership of these shares.
• The reported share and warrant numbers reflect a 1-for-9 reverse share split effected by Silexion Therapeutics Corp on November 29, 2024, and a 1-for-15 reverse share split effected on July 29, 2025.
• Ilan Levin indirectly holds 1,482 ordinary shares through Greenstar, L.P., for informational purposes only, with no transactions reported for these specific holdings.

Sentiment

Score: 3

Explanation: The filing indicates significant negative developments, primarily due to the explicit dispute over a large share issuance and the occurrence of two substantial reverse stock splits. These factors suggest severe underlying issues, potential corporate governance problems, and financial distress, creating high uncertainty and risk for investors.

Negatives

• Reporting persons expressly dispute the validity of the issuance of 450,000 ordinary shares, indicating potential internal conflict or legal challenges regarding ownership.
• The company effected two significant reverse share splits (1-for-9 on November 29, 2024, and 1-for-15 on July 29, 2025), which often signal a declining stock price and potential underlying financial or operational distress.

Risks

• Potential legal disputes or internal conflict regarding the validity and beneficial ownership of 450,000 ordinary shares issued to Moringa Sponsor, LP.
• Risk of further share price decline and reduced liquidity following two substantial reverse stock splits.
• Uncertainty surrounding the company's financial health, as reverse splits are often used to maintain listing requirements or improve share price perception for struggling companies.
• Potential for further dilution if the convertible promissory note has remaining principal or if other convertible instruments exist.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance beyond the reported transactions and adjustments.

Management Comments

• "The Reporting Persons expressly dispute the validity of the subject issuance and do not concede beneficial ownership of those 450,000 shares."

Industry Context

Form 4 filings are standard disclosures for insiders reporting changes in beneficial ownership. However, the explicit dispute over a significant share issuance and the occurrence of two reverse stock splits are unusual and suggest potential internal strife or severe financial challenges for Silexion Therapeutics Corp. Reverse splits are often a last resort for companies to maintain stock exchange listing requirements or to artificially boost share price perception, typically indicating underlying operational or financial distress.

Comparison to Industry Standards

• The occurrence of two reverse stock splits (1-for-9 and 1-for-15) within a short period is significantly worse than industry standards, as it often signals severe financial distress or a rapidly declining stock price, unlike stable, growing companies.
• The explicit dispute by reporting persons (including a director and 10% owner) regarding the validity of a 450,000 share issuance is highly unusual and problematic, suggesting potential corporate governance failures or legal conflicts, which is a stark contrast to standard, undisputed insider transactions in healthy companies.

Legal Proceedings

• The explicit dispute by reporting persons regarding the validity of the 450,000 share issuance suggests a high likelihood of ongoing or impending legal proceedings or significant internal corporate conflict.

Related Party Transactions

• Pro rata distribution of ordinary shares and warrants by Moringa Sponsor, LP. (a 10% owner controlled by Ilan Levin, a director) to its limited partners for no consideration.
• Issuance of 450,000 ordinary shares to Moringa Sponsor, LP. upon conversion of a $1,800,000 convertible promissory note, where Moringa Sponsor, LP. is a 10% owner and controlled by director Ilan Levin.

Stakeholder Impact

• Shareholders face increased uncertainty and potential dilution due to the disputed share issuance and the implications of the reverse stock splits on share price and liquidity.
• The dispute may signal internal conflict within management or the board, potentially impacting company stability and decision-making.
• Creditors holding convertible notes may see their debt converted to equity, but the dispute adds complexity to the transaction's finality.

Next Steps

• Resolution of the dispute regarding the validity and beneficial ownership of the 450,000 ordinary shares issued to Moringa Sponsor, LP.
• Further disclosures or updates regarding the company's financial performance and strategic direction, especially in light of the reverse stock splits.

Key Dates

Recommendation

The filing reveals critical red flags, including an explicit dispute over the validity of a 450,000 share issuance to a significant insider entity and two recent, substantial reverse stock splits. These factors strongly indicate severe underlying financial distress, potential corporate governance failures, and significant legal or internal conflicts. Such conditions create extreme uncertainty and high risk, making the stock highly unattractive for investment and suggesting a strong likelihood of further value erosion.

Keywords

Silexion Therapeutics, SLXN, Form 4, beneficial ownership, insider trading, reverse stock split, convertible note, warrant, Ilan Levin, Moringa Sponsor